Effect of Usnic Acid-Derived Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Used as Monotherapy or in Combination with Olaparib on Transplanted Tumors in vivo Научная публикация
Журнал |
Molecular Biology
ISSN: 0026-8933 |
||||||||
---|---|---|---|---|---|---|---|---|---|
Вых. Данные | Год: 2023, Том: 57, Номер: 2, Страницы: 220-231 Страниц : 12 DOI: 10.1134/S0026893323020127 | ||||||||
Авторы |
|
||||||||
Организации |
|
Реферат:
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a DNA repair enzyme that removes various adducts from the 3' end of DNA. Such adducts are formed by enzymes that introduce single-strand breaks in DNA during catalysis (for example, topoisomerase 1) and a number of anticancer drugs with different mechanisms of action. Poly(ADP-ribose) polymerase 1 (PARP1) is an enzyme that catalyzes posttranslational modification (PARylation) of various targets and thus controls many cell processes, including DNA repair. Tdp1 is a PARP1 target, and its PARylation attracts Tdp1 to the site of DNA damage. Olaparib is a PARP1 inhibitor used in clinical practice to treat homologous recombination-deficient tumors. Olaparib inhibits PARylation and, therefore, DNA repair. The Tdp1 inhibitor OL7-43 was used in combination with olaparib to increase the antitumor effect of the latter. Olaparib cytotoxicity was found to increase in the presence of OL7-43 in vitro. OL7-43 did not exert a sensitizing effect, but showed its own antitumor and antimetastatic effects in Lewis and Krebs-2 carcinoma models.
Библиографическая ссылка:
Kornienko T.E.
, Zakharenko A.L.
, Ilina E.S.
, Chepanova A.A.
, Zakharova O.
, Dyrkheeva N.S.
, Popova N.A.
, Nikolin V.P.
, Filimonov A.S.
, Luzina O.A.
, Salakhutdinov N.F.
, Lavrik O.I.
Effect of Usnic Acid-Derived Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Used as Monotherapy or in Combination with Olaparib on Transplanted Tumors in vivo
Molecular Biology. 2023. V.57. N2. P.220-231. DOI: 10.1134/S0026893323020127 WOS Scopus OpenAlex
Effect of Usnic Acid-Derived Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Used as Monotherapy or in Combination with Olaparib on Transplanted Tumors in vivo
Molecular Biology. 2023. V.57. N2. P.220-231. DOI: 10.1134/S0026893323020127 WOS Scopus OpenAlex
Оригинальная:
Корниенко Т.Е.
, Захаренко А.Л.
, Ильина Е.С.
, Чепанова А.А.
, Захарова О.Д.
, Дырхеева Н.С.
, Попова Н.А.
, Николин В.П.
, Филимонов А.С.
, Лузина О.А.
, Салахутдинов Н.Ф.
, Лаврик О.И.
Влияние производного усниновой кислоты (ингибитора тирозил-ДНК-фосфодиэстеразы 1) на трансплантированные опухоли in vivo в качестве монотерапии и в сочетании с олапарибом
Молекулярная биология. 2023. Т.57. №2. С.220-231. DOI: 10.31857/S0026898423020143 РИНЦ OpenAlex
Влияние производного усниновой кислоты (ингибитора тирозил-ДНК-фосфодиэстеразы 1) на трансплантированные опухоли in vivo в качестве монотерапии и в сочетании с олапарибом
Молекулярная биология. 2023. Т.57. №2. С.220-231. DOI: 10.31857/S0026898423020143 РИНЦ OpenAlex
Даты:
Опубликована в печати: | 26 апр. 2023 г. |
Идентификаторы БД:
Web of science: | WOS:000984409600007 |
Scopus: | 2-s2.0-85156165338 |
OpenAlex: | W4367056603 |